Free Trial
NASDAQ:LONA

Athira Pharma Q1 2025 Earnings Results & Report

Athira Pharma logo
$3.23 -0.24 (-6.92%)
As of 03:54 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Athira Pharma missed analyst earnings expectations in its Q1 2025 results, released May 9, 2025. The company reported EPS of -$2.30 versus the -$2.00 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

Athira Pharma EPS Results

Actual EPS
-$2.30
Consensus EPS
-$2.00
Beat/Miss
Missed by -$0.30
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Athira Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Athira Pharma Q1 2025 Earnings FAQ

Athira Pharma (NASDAQ:LONA) reported earnings of -$2.30 per share for Q1 2025, missing the consensus estimate of -$2.00. The report was announced on Friday, May 9, 2025.

Athira Pharma Earnings Headlines

What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
See More Athira Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Athira Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Athira Pharma and other key companies, straight to your email.

About Athira Pharma

Athira Pharma (NASDAQ:LONA) is a clinical-stage biopharmaceutical company based in Bothell, Washington, that focused on developing treatments for neurodegenerative diseases and other conditions affecting the brain. Its research centered on the hepatocyte growth factor (HGF) and MET biological system, which is involved in neuronal health and repair.

The company’s pipeline included fosgonimeton, an investigational therapy studied for Alzheimer’s disease and dementia associated with Parkinson’s disease, as well as ATH-1105, a small-molecule candidate investigated for amyotrophic lateral sclerosis. These were development-stage candidates, not approved medicines.

Athira was founded in 2011 and advanced its programs through clinical research. Fosgonimeton did not meet the primary endpoints in a Phase 3 Alzheimer’s disease study, and the company subsequently reassessed its development plans.

View Athira Pharma Profile